WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the second quarter ended June 30, 2025, and provided a strategic business update.
Related Questions
Did the company meet or miss Wall Street consensus estimates for earnings per share and revenue?
Did management comment on any macroeconomic or regulatory risks that could impact the business?
What were the key financial metrics (revenue, net loss, cash burn) for Q2 2025, and how do they compare to the same quarter last year?
What guidance did the company provide for Q3 2025 and the full fiscal year 2025, and how does it compare to analyst forecasts?
Are there any new product or pipeline milestones announced that could affect future revenue streams?
What is the market's reaction (price movement, volume) to this release, and how does it compare to previous earnings releases?
Did the company disclose any new partnership, licensing or acquisition agreements in the update?
How does the current cash position and runway compare to prior quarters, and what are the implications for upcoming R&D spending?
What is the status of the company's key clinical trials, and are there any upcoming FDA or EMA decision dates?
How does the company's operating expense trend look, especially R&D and SG&A, and what does that indicate about cost management?
What were the reasons for any changes in the company's share count (e.g., dilution, buybacks, stock options) during the quarter?
How does the company's performance compare with its direct competitors in the same therapeutic area?